Biotech Values

[mcbio]

Re: JNCE

Interesting. When I looked into this one, my personal conclusion was that the preclinical data rationalized a CTLA-4 combination but did not support a PD-(L)1 combination.

Do you give JNCE a shot to show a signal in the next trial combining JTX-2011 with ipilimumab or does the fact that management didn't pick up on this combo before give you overall pause?

Not saying this one will be the winner but, in general, it almost feels to me that the pendulum has swung far too far the other way in terms of IO hype. It feels to me like a lot of the small-cap IO biotechs are being priced as if there is unlikely to be much progress in the coming years. Seems a bit extreme to me so I'm looking for some exposure here again.